John Boniface
Chief Tech/Sci/R&D Officer bij SERA PROGNOSTICS, INC.
Vermogen: 1 M $ op 29-02-2024
Profiel
John J.
Boniface holds the position of Chief Scientific Officer for Sera Prognostics, Inc.
He previously occupied the position of Vice President-Science at Bioinformatics Solutions, Inc., Program Director at Myriad Genetics, Inc., Program Director at Myrexis, Inc., Program Director at Prolexys Pharmaceuticals, Inc. and Program Director at EOS Biotechnology, Inc.
Dr. Boniface received a doctorate from Albany Medical College and an undergraduate degree from the University of Massachusetts.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
26-03-2024 | 143 524 ( 0.47% ) | 1 M $ | 29-02-2024 |
Actieve functies van John Boniface
Bedrijven | Functie | Begin |
---|---|---|
SERA PROGNOSTICS, INC. | Chief Tech/Sci/R&D Officer | 01-11-2011 |
Eerdere bekende functies van John Boniface
Bedrijven | Functie | Einde |
---|---|---|
Bioinformatics Solutions, Inc.
Bioinformatics Solutions, Inc. Packaged SoftwareTechnology Services Bioinformatics Solutions, Inc. develops and innovate PEAKS software platform. The firm products are discovery, antibody based, and PEAKS components identify and quantify proteins in very complex biological samples with LC-MS. It also focused on serving the proteomics research community. The company was founded in 2000 and is headquartered in Waterloo, Canada. | Chief Tech/Sci/R&D Officer | - |
EOS Biotechnology, Inc.
EOS Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California. | Corporate Officer/Principal | - |
MYRIAD GENETICS, INC. | Corporate Officer/Principal | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Corporate Officer/Principal | - |
MYREXIS, INC. | Corporate Officer/Principal | - |
Opleiding van John Boniface
University of Massachusetts | Undergraduate Degree |
Albany Medical College | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
MYRIAD GENETICS, INC. | Health Technology |
MYREXIS, INC. | Finance |
Bedrijven in privébezit | 4 |
---|---|
EOS Biotechnology, Inc.
EOS Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California. | Health Technology |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
Sera Prognostics, Inc. | |
Bioinformatics Solutions, Inc.
Bioinformatics Solutions, Inc. Packaged SoftwareTechnology Services Bioinformatics Solutions, Inc. develops and innovate PEAKS software platform. The firm products are discovery, antibody based, and PEAKS components identify and quantify proteins in very complex biological samples with LC-MS. It also focused on serving the proteomics research community. The company was founded in 2000 and is headquartered in Waterloo, Canada. | Technology Services |